Spectris™ treatment is associated with significant time saved in the OVERTURE feasibility and open label extension (OLE) study

Abstract

Background: The OVERTURE (NCT03556280) randomized controlled trial (RCT) ¹ and open label extension (OLE) evaluated investigational evoked brain gamma oscillations (Spectris™), in mild‐moderate Alzheimer’s disease (AD).

The paper